Symbols / ATOS Stock $5.16 +0.00% Atossa Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
ATOS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Steven C. Quay FCAP, M.D., Ph.D.
Exch · Country NCM · United States
Market Cap 44.43M
Enterprise Value 6.92M
Income -34.77M
Sales —
FCF (ttm) -18.23M
Book/sh 4.57
Cash/sh 4.80
Employees 16
Insider 10d —
IPO Nov 08, 2012
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.18
PEG —
P/S —
P/B 1.13
P/C —
EV/EBITDA -0.19
EV/Sales —
Quick Ratio 5.00
Current Ratio 5.53
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -4.37
EPS next Y -4.38
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-08
Earnings (prior) 2026-05-08
ROA -37.43%
ROE -62.74%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 8.61M
Shs Float 8.61M
Insider Own 0.83%
Instit Own 22.06%
Short Float 4.09%
Short Ratio 5.12
Short Interest 351.93K
52W High 19.35
vs 52W High -73.33%
52W Low 3.76
vs 52W Low 37.23%
Beta 1.25
Impl. Vol. 6.25%
Rel Volume 0.42
Avg Volume 72.14K
Volume 29.98K
Target (mean) $23.00
Tgt Median $24.00
Tgt Low $20.00
Tgt High $25.00
# Analysts 3
Recom Strong_buy
Prev Close $5.16
Price $5.16
Change 0.00%
About

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$23.00
Mean price target
2. Current target
$5.16
Latest analyst target
3. DCF / Fair value
$-38.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.16
Low
$20.00
High
$25.00
Mean
$23.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-10 main Ascendiant Capital Buy → Buy $24
2026-03-26 main HC Wainwright & Co. Buy → Buy $25
2025-12-08 main Ascendiant Capital Buy → Buy $8
2025-09-22 main Ascendiant Capital Buy → Buy $8
2025-06-06 main Ascendiant Capital Buy → Buy $8
2025-06-05 init Craig-Hallum — → Buy $4
2025-04-21 main Ascendiant Capital Buy → Buy $7
2025-03-26 reit HC Wainwright & Co. Buy → Buy $7
2025-03-12 reit HC Wainwright & Co. Buy → Buy $7
2025-01-30 reit HC Wainwright & Co. Buy → Buy $7
2024-12-13 reit HC Wainwright & Co. Buy → Buy $7
2024-12-12 reit HC Wainwright & Co. Buy → Buy —
2024-12-09 main Ascendiant Capital Buy → Buy $7
2024-11-13 main HC Wainwright & Co. Buy → Buy $7
2024-11-05 reit HC Wainwright & Co. Buy → Buy $6
2024-10-31 reit HC Wainwright & Co. Buy → Buy $6
2024-09-11 main Ascendiant Capital Buy → Buy $7
2024-08-12 reit HC Wainwright & Co. Buy → Buy $6
2024-06-28 reit HC Wainwright & Co. Buy → Buy $6
2024-06-20 reit Cantor Fitzgerald — → Overweight —
News
RSS: Latest ATOS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-27 QUAY STEVEN C Chief Executive Officer — 65,000 $0.00 $0
2026-03-26 DANIEL MARK JAMES CPA Chief Financial Officer — 63,000 $0.00 $0
2026-01-20 QUAY STEVEN C Chief Executive Officer — 325,203 — —
2026-01-20 QUAY STEVEN C Chief Executive Officer — 331,674 — —
2025-05-21 QUAY STEVEN C Chief Executive Officer — 11,239 $0.88 $9,887
2025-03-26 REMMEL H LAWRENCE Director — 10,000 $0.70 $7,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
37.14
+34.47%
27.62
-11.97%
31.38
+13.31%
27.69
Research And Development
21.18
+50.07%
14.12
-18.56%
17.33
+14.92%
15.08
Selling General And Administration
15.96
+18.16%
13.50
-3.84%
14.04
+11.38%
12.61
General And Administrative Expense
15.96
+18.16%
13.50
-3.84%
14.04
+11.38%
12.61
Other Gand A
15.96
+18.16%
13.50
-3.84%
14.04
+11.38%
12.61
Total Expenses
37.14
+34.47%
27.62
-11.97%
31.38
+13.31%
27.69
Operating Income
-37.14
-34.47%
-27.62
+11.97%
-31.38
-13.31%
-27.69
Total Operating Income As Reported
-37.14
-34.47%
-27.62
+11.97%
-31.38
-13.31%
-27.69
EBITDA
-37.12
-34.49%
-27.60
+11.96%
-31.35
-13.26%
-27.68
Normalized EBITDA
-37.12
-43.37%
-25.89
+8.71%
-28.36
-2.46%
-27.68
Reconciled Depreciation
0.02
-5.88%
0.02
-26.09%
0.02
+187.50%
0.01
EBIT
-37.14
-34.47%
-27.62
+11.97%
-31.38
-13.31%
-27.69
Total Unusual Items
0.00
+100.00%
-1.71
+42.81%
-2.99
0.00
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-1.71
+42.81%
-2.99
0.00
Special Income Charges
0.00
+100.00%
-1.71
+42.81%
-2.99
0.00
Write Off
0.00
-100.00%
1.71
-42.81%
2.99
0.00
Net Income
-34.77
-36.33%
-25.50
+15.25%
-30.09
-11.62%
-26.96
Pretax Income
-34.77
-36.33%
-25.50
+15.25%
-30.09
-11.62%
-26.96
Net Non Operating Interest Income Expense
2.38
-41.31%
4.05
-6.75%
4.34
+395.21%
0.88
Net Interest Income
2.38
-41.31%
4.05
-6.75%
4.34
+395.21%
0.88
Interest Income Non Operating
2.38
-41.31%
4.05
-6.75%
4.34
+395.21%
0.88
Interest Income
2.38
-41.31%
4.05
-6.75%
4.34
+395.21%
0.88
Other Income Expense
-0.01
+99.69%
-1.93
+36.83%
-3.06
-1995.89%
-0.15
Other Non Operating Income Expenses
-0.01
+97.31%
-0.22
-218.57%
-0.07
+52.05%
-0.15
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-34.77
-36.33%
-25.50
+15.25%
-30.09
-11.62%
-26.96
Net Income From Continuing Operation Net Minority Interest
-34.77
-36.33%
-25.50
+15.25%
-30.09
-11.62%
-26.96
Net Income From Continuing And Discontinued Operation
-34.77
-36.33%
-25.50
+15.25%
-30.09
-11.62%
-26.96
Net Income Continuous Operations
-34.77
-36.33%
-25.50
+15.25%
-30.09
-11.62%
-26.96
Normalized Income
-34.77
-46.13%
-23.79
+12.21%
-27.10
-0.53%
-26.96
Net Income Common Stockholders
-34.77
-36.33%
-25.50
+15.25%
-30.09
-11.62%
-26.96
Diluted EPS
-4.04
-32.89%
-3.04
+15.56%
-3.60
-14.29%
-3.15
Basic EPS
-4.04
-32.89%
-3.04
+15.56%
-3.60
-14.29%
-3.15
Basic Average Shares
8.61
+2.63%
8.39
-0.18%
8.41
-0.43%
8.44
Diluted Average Shares
8.61
+2.63%
8.39
-0.18%
8.41
-0.43%
8.44
Diluted NI Availto Com Stockholders
-34.77
-36.33%
-25.50
+15.25%
-30.09
-11.62%
-26.96
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
47.61
-37.72%
76.44
-20.58%
96.25
Current Assets
45.62
-38.73%
74.46
-19.26%
92.22
Cash Cash Equivalents And Short Term Investments
41.30
-41.90%
71.08
-19.64%
88.46
Cash And Cash Equivalents
41.30
-41.90%
71.08
-19.64%
88.46
Receivables
—
—
0.00
Taxes Receivable
—
—
0.00
Prepaid Assets
4.08
+29.64%
3.14
-12.35%
3.59
Restricted Cash
0.11
+0.00%
0.11
+0.00%
0.11
Other Current Assets
0.13
+11.76%
0.12
+91.94%
0.06
Total Non Current Assets
1.99
+0.15%
1.99
-50.73%
4.03
Net PPE
—
—
—
Gross PPE
—
—
—
Accumulated Depreciation
—
—
—
Machinery Furniture Equipment
—
—
—
Goodwill And Other Intangible Assets
—
—
—
Investments And Advances
—
0.00
-100.00%
1.71
Long Term Equity Investment
—
—
—
Other Non Current Assets
1.99
+0.15%
1.99
-14.46%
2.32
Total Liabilities Net Minority Interest
8.26
+66.20%
4.97
-5.14%
5.24
Current Liabilities
8.26
+66.20%
4.97
-5.14%
5.24
Payables And Accrued Expenses
6.26
+224.78%
1.93
-6.50%
2.06
Payables
4.29
+532.25%
0.68
-15.76%
0.81
Accounts Payable
4.29
+532.25%
0.68
-15.76%
0.81
Current Accrued Expenses
1.97
+57.76%
1.25
-0.56%
1.26
Pensionand Other Post Retirement Benefit Plans Current
0.89
-41.67%
1.53
+11.75%
1.37
Current Capital Lease Obligation
—
—
—
Other Current Liabilities
1.10
-27.21%
1.51
-16.42%
1.80
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
Stockholders Equity
39.35
-44.94%
71.48
-21.47%
91.02
Common Stock Equity
39.35
-44.94%
71.48
-21.47%
91.02
Capital Stock
1.55
+0.00%
1.55
-93.20%
22.79
Common Stock
1.55
+0.00%
1.55
-93.20%
22.79
Preferred Stock
0.00
0.00
0.00
Share Issued
8.70
+0.00%
8.70
+3.05%
8.44
Ordinary Shares Number
8.61
+0.00%
8.61
+3.09%
8.35
Treasury Shares Number
0.09
+0.00%
0.09
+0.00%
0.09
Additional Paid In Capital
285.84
+0.93%
283.19
+10.63%
255.99
Retained Earnings
-246.56
-16.42%
-211.79
-13.69%
-186.29
Treasury Stock
1.48
+0.00%
1.48
+0.00%
1.48
Total Equity Gross Minority Interest
39.35
-44.94%
71.48
-21.47%
91.02
Total Capitalization
39.35
-44.94%
71.48
-21.47%
91.02
Working Capital
37.36
-46.23%
69.49
-20.11%
86.98
Invested Capital
39.35
-44.94%
71.48
-21.47%
91.02
Total Debt
—
—
—
Capital Lease Obligations
—
—
—
Net Tangible Assets
39.35
-44.94%
71.48
-21.47%
91.02
Tangible Book Value
39.35
-44.94%
71.48
-21.47%
91.02
Available For Sale Securities
—
—
1.71
Investmentin Financial Assets
—
0.00
-100.00%
1.71
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-29.76
-41.52%
-21.03
-0.43%
-20.94
-0.87%
-20.76
Cash Flow From Continuing Operating Activities
-29.76
-41.52%
-21.03
-0.43%
-20.94
-0.87%
-20.76
Net Income From Continuing Operations
-34.77
-36.33%
-25.50
+15.25%
-30.09
-11.62%
-26.96
Depreciation Amortization Depletion
0.02
-5.88%
0.02
-26.09%
0.02
+187.50%
0.01
Depreciation
0.02
-5.88%
0.02
-26.09%
0.02
—
Depreciation And Amortization
0.02
-5.88%
0.02
-26.09%
0.02
+187.50%
0.01
Stock Based Compensation
2.65
+15.45%
2.29
-50.40%
4.62
-31.92%
6.79
Asset Impairment Charge
0.00
-100.00%
1.71
-42.81%
2.99
0.00
Operating Gains Losses
—
0.01
—
0.00
Change In Working Capital
2.35
+423.66%
0.45
-70.51%
1.52
+353.59%
-0.60
Change In Receivables
—
—
0.74
+125.84%
0.33
Change In Prepaid Assets
-0.95
-345.08%
0.39
-89.12%
3.55
+227.95%
-2.77
Change In Payables And Accrued Expense
4.00
+2311.05%
-0.18
+91.94%
-2.25
-206.75%
2.10
Change In Accrued Expense
0.39
+818.52%
-0.05
+37.21%
-0.09
-110.06%
0.85
Change In Payable
3.61
+2945.67%
-0.13
+94.12%
-2.16
-273.00%
1.25
Change In Account Payable
3.61
+2945.67%
-0.13
+94.12%
-2.16
-273.00%
1.25
Change In Other Working Capital
-0.30
-246.15%
0.21
+61.24%
0.13
-62.17%
0.34
Change In Other Current Assets
0.00
-98.79%
0.33
+119.51%
-1.70
-184.25%
-0.60
Change In Other Current Liabilities
-0.41
-38.51%
-0.30
-116.59%
1.78
+89300.00%
-0.00
Investing Cash Flow
-0.02
-21.05%
-0.02
-35.71%
-0.01
+99.70%
-4.73
Cash Flow From Continuing Investing Activities
-0.02
-21.05%
-0.02
-35.71%
-0.01
+99.70%
-4.73
Net PPE Purchase And Sale
-0.02
-21.05%
-0.02
-35.71%
-0.01
+48.15%
-0.03
Purchase Of PPE
-0.02
-21.05%
-0.02
-35.71%
-0.01
+48.15%
-0.03
Capital Expenditure
-0.02
-21.05%
-0.02
-35.71%
-0.01
+48.15%
-0.03
Net Investment Purchase And Sale
—
—
0.00
+100.00%
-4.70
Purchase Of Investment
—
—
0.00
+100.00%
-4.70
Financing Cash Flow
0.00
-100.00%
3.67
+349.02%
-1.48
0.00
Cash Flow From Continuing Financing Activities
0.00
-100.00%
3.67
+349.02%
-1.48
0.00
Net Common Stock Issuance
—
0.00
+100.00%
-1.48
0.00
Common Stock Payments
—
0.00
+100.00%
-1.48
0.00
Repurchase Of Capital Stock
—
0.00
+100.00%
-1.48
0.00
Proceeds From Stock Option Exercised
0.00
-100.00%
3.67
0.00
0.00
Net Other Financing Charges
—
—
—
—
Changes In Cash
-29.79
-71.41%
-17.38
+22.53%
-22.43
+11.99%
-25.49
Beginning Cash Position
71.19
-19.62%
88.57
-20.21%
111.00
-18.67%
136.49
End Cash Position
41.41
-41.84%
71.19
-19.62%
88.57
-20.21%
111.00
Free Cash Flow
-29.79
-41.50%
-21.05
-0.45%
-20.95
-0.81%
-20.79
Common Stock Issuance
—
—
—
0.00
Issuance Of Capital Stock
—
—
—
0.00
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category